Another possibility for PCa patients with ATM mutations is the therapeutic application of ATM inhibitors, such as AZD1390, AZD0156, M4076, Ku 60019 or XRD-0394, but these inhibitors are still in clinical phase I studies. This evidence concerns the gene ATM and posterior cortical atrophy.